We read the context, not just the contract
A SOW describes the work. The context tells you what the work is actually for. We pay attention to both.
Why Preciviaa
Rigorous by design.
Clinical trial biometrics built for regulatory scrutiny — with the right assumptions, the right people, and the right decisions made before they become expensive.
The deeper value
Execution rigour is expected. Clean data, compliant outputs, on-time delivery. That's the entry ticket. Context rigour is where experience changes the outcome.
Context rigour is knowing which molecule matters to the sponsor. Knowing when a budget assumption is no longer valid. Knowing that the right long term commercial move is to absorb scope — because the relationship and the study are both worth more than a short-term invoice dispute.
This judgement comes from having been in enough rooms, on enough studies, across enough sponsors to know what you're actually looking at. We bring that to every engagement — not as a differentiator we claim on a slide, but as the standard we hold ourselves to.
We make assumptions visible
Unspoken assumptions are easier to manage when they are surfaced early.
We are close to the work
Not supervising from a distance. In the detail, on the timelines, across the review cycles — because that's where the real decisions get made.
We build for scrutiny
Every deliverable is prepared as if a regulator, a sponsor, or a sceptical statistician will ask the hard question next week. Because one of them usually does.
Who we work with
Teams who know the difference between a vendor and a partner.
01Biotech companies
02Pharmaceutical biometrics teams
03Boutique CROs
04Growing biometrics groups
05FSP and functional teams
06Audit and inspection-preparation teams
Ready to talk?